SARTORIUS STEDIM BIOTECH (DIM.PA) Fundamental Analysis & Valuation
EPA:DIM • FR0013154002
Current stock price
165 EUR
-2.05 (-1.23%)
Last:
This DIM.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. DIM.PA Profitability Analysis
1.1 Basic Checks
- DIM had positive earnings in the past year.
- In the past year DIM had a positive cash flow from operations.
- In the past 5 years DIM has always been profitable.
- In the past 5 years DIM always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 3.33%, DIM is in line with its industry, outperforming 44.44% of the companies in the same industry.
- With a Return On Equity value of 6.50%, DIM perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
- DIM has a Return On Invested Capital (6.11%) which is comparable to the rest of the industry.
- Measured over the past 3 years, the Average Return On Invested Capital for DIM is below the industry average of 9.34%.
- The 3 year average ROIC (5.23%) for DIM is below the current ROIC(6.11%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.33% | ||
| ROE | 6.5% | ||
| ROIC | 6.11% |
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
1.3 Margins
- With a decent Profit Margin value of 8.96%, DIM is doing good in the industry, outperforming 61.11% of the companies in the same industry.
- DIM's Profit Margin has declined in the last couple of years.
- DIM has a better Operating Margin (17.72%) than 61.11% of its industry peers.
- In the last couple of years the Operating Margin of DIM has declined.
- The Gross Margin of DIM (45.33%) is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of DIM has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.72% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.33% |
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
2. DIM.PA Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DIM is destroying value.
- DIM has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for DIM has been increased compared to 5 years ago.
- Compared to 1 year ago, DIM has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 3.82 indicates that DIM is not in any danger for bankruptcy at the moment.
- DIM has a better Altman-Z score (3.82) than 83.33% of its industry peers.
- DIM has a debt to FCF ratio of 8.69. This is a slightly negative value and a sign of low solvency as DIM would need 8.69 years to pay back of all of its debts.
- With a Debt to FCF ratio value of 8.69, DIM perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
- A Debt/Equity ratio of 0.49 indicates that DIM is not too dependend on debt financing.
- DIM's Debt to Equity ratio of 0.49 is fine compared to the rest of the industry. DIM outperforms 61.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 8.69 | ||
| Altman-Z | 3.82 |
ROIC/WACC0.65
WACC9.45%
2.3 Liquidity
- A Current Ratio of 1.02 indicates that DIM should not have too much problems paying its short term obligations.
- With a Current ratio value of 1.02, DIM is not doing good in the industry: 72.22% of the companies in the same industry are doing better.
- A Quick Ratio of 0.53 indicates that DIM may have some problems paying its short term obligations.
- DIM has a worse Quick ratio (0.53) than 72.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.53 |
3. DIM.PA Growth Analysis
3.1 Past
- DIM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.71%, which is quite impressive.
- Measured over the past 5 years, DIM shows a small growth in Earnings Per Share. The EPS has been growing by 1.13% on average per year.
- Looking at the last year, DIM shows a small growth in Revenue. The Revenue has grown by 6.74% in the last year.
- Measured over the past years, DIM shows a quite strong growth in Revenue. The Revenue has been growing by 9.21% on average per year.
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.78%
3.2 Future
- DIM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.04% yearly.
- Based on estimates for the next years, DIM will show a quite strong growth in Revenue. The Revenue will grow by 11.26% on average per year.
EPS Next Y19.6%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
EPS Next 5Y19.04%
Revenue Next Year7.44%
Revenue Next 2Y9.02%
Revenue Next 3Y9.46%
Revenue Next 5Y11.26%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. DIM.PA Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 37.50, the valuation of DIM can be described as expensive.
- Based on the Price/Earnings ratio, DIM is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
- When comparing the Price/Earnings ratio of DIM to the average of the S&P500 Index (24.88), we can say DIM is valued expensively.
- With a Price/Forward Earnings ratio of 31.35, DIM can be considered very expensive at the moment.
- DIM's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. DIM is more expensive than 66.67% of the companies in the same industry.
- DIM's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.5 | ||
| Fwd PE | 31.35 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, DIM is valued a bit more expensive than 66.67% of the companies in the same industry.
- DIM's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.71 | ||
| EV/EBITDA | 21.79 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DIM does not grow enough to justify the current Price/Earnings ratio.
- DIM's earnings are expected to grow with 19.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.91
PEG (5Y)33.24
EPS Next 2Y19.98%
EPS Next 3Y19.05%
5. DIM.PA Dividend Analysis
5.1 Amount
- With a yearly dividend of 0.41%, DIM is not a good candidate for dividend investing.
- DIM's Dividend Yield is comparable with the industry average which is at 0.52.
- With a Dividend Yield of 0.41, DIM pays less dividend than the S&P500 average, which is at 1.89.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
5.2 History
- The dividend of DIM is nicely growing with an annual growth rate of 15.19%!
Dividend Growth(5Y)15.19%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
- 25.24% of the earnings are spent on dividend by DIM. This is a low number and sustainable payout ratio.
- The dividend of DIM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.24%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
DIM.PA Fundamentals: All Metrics, Ratios and Statistics
EPA:DIM (3/27/2026, 7:00:00 PM)
165
-2.05 (-1.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03 2026-02-03/bmo
Earnings (Next)04-23 2026-04-23
Inst Owners11.98%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.06B
Revenue(TTM)2.97B
Net Income(TTM)265.80M
Analysts78.95
Price Target240.49 (45.75%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.41% |
Yearly Dividend0.69
Dividend Growth(5Y)15.19%
DP25.24%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.48%
Min EPS beat(2)-12.72%
Max EPS beat(2)-2.24%
EPS beat(4)2
Avg EPS beat(4)4.36%
Min EPS beat(4)-12.72%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.28%
EPS beat(12)3
Avg EPS beat(12)-11.72%
EPS beat(16)3
Avg EPS beat(16)-14.26%
Revenue beat(2)0
Avg Revenue beat(2)-4.06%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)-3.94%
Revenue beat(4)2
Avg Revenue beat(4)-1.07%
Min Revenue beat(4)-4.17%
Max Revenue beat(4)3.52%
Revenue beat(8)4
Avg Revenue beat(8)-1.65%
Revenue beat(12)5
Avg Revenue beat(12)-1.63%
Revenue beat(16)6
Avg Revenue beat(16)-1.17%
PT rev (1m)-2.03%
PT rev (3m)0.33%
EPS NQ rev (1m)-1.22%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.39%
EPS NY rev (3m)-1.16%
Revenue NQ rev (1m)-5.86%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.14%
Revenue NY rev (3m)-2.98%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.5 | ||
| Fwd PE | 31.35 | ||
| P/S | 5.41 | ||
| P/FCF | 53.71 | ||
| P/OCF | 23.2 | ||
| P/B | 3.93 | ||
| P/tB | N/A | ||
| EV/EBITDA | 21.79 |
EPS(TTM)4.4
EY2.67%
EPS(NY)5.26
Fwd EY3.19%
FCF(TTM)3.07
FCFY1.86%
OCF(TTM)7.11
OCFY4.31%
SpS30.49
BVpS42.03
TBVpS-3.39
PEG (NY)1.91
PEG (5Y)33.24
Graham Number64.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.33% | ||
| ROE | 6.5% | ||
| ROCE | 8% | ||
| ROIC | 6.11% | ||
| ROICexc | 6.56% | ||
| ROICexgc | 23.58% | ||
| OM | 17.72% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.33% | ||
| FCFM | 10.08% |
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
ROICexc(3y)5.56%
ROICexc(5y)12.62%
ROICexgc(3y)18.67%
ROICexgc(5y)31.48%
ROCE(3y)6.85%
ROCE(5y)15.55%
ROICexgc growth 3Y-18%
ROICexgc growth 5Y-10.32%
ROICexc growth 3Y-31.81%
ROICexc growth 5Y-17.24%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
F-Score7
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 8.69 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 123.61% | ||
| Cap/Sales | 13.25% | ||
| Interest Coverage | 3.42 | ||
| Cash Conversion | 82.03% | ||
| Profit Quality | 112.49% | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.53 | ||
| Altman-Z | 3.82 |
F-Score7
WACC9.45%
ROIC/WACC0.65
Cap/Depr(3y)145.19%
Cap/Depr(5y)180.27%
Cap/Sales(3y)14.18%
Cap/Sales(5y)13.22%
Profit Quality(3y)157.37%
Profit Quality(5y)116.81%
High Growth Momentum
Growth
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
EPS Next Y19.6%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
EPS Next 5Y19.04%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.78%
Revenue Next Year7.44%
Revenue Next 2Y9.02%
Revenue Next 3Y9.46%
Revenue Next 5Y11.26%
EBIT growth 1Y41.93%
EBIT growth 3Y-20.72%
EBIT growth 5Y1.39%
EBIT Next Year55.74%
EBIT Next 3Y26.51%
EBIT Next 5Y22.89%
FCF growth 1Y-37.09%
FCF growth 3Y18.06%
FCF growth 5Y3.02%
OCF growth 1Y-15.08%
OCF growth 3Y4.17%
OCF growth 5Y10.67%
SARTORIUS STEDIM BIOTECH / DIM.PA Fundamental Analysis FAQ
What is the fundamental rating for DIM stock?
ChartMill assigns a fundamental rating of 5 / 10 to DIM.PA.
What is the valuation status of SARTORIUS STEDIM BIOTECH (DIM.PA) stock?
ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (DIM.PA). This can be considered as Overvalued.
What is the profitability of DIM stock?
SARTORIUS STEDIM BIOTECH (DIM.PA) has a profitability rating of 5 / 10.
What are the PE and PB ratios of SARTORIUS STEDIM BIOTECH (DIM.PA) stock?
The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (DIM.PA) is 37.5 and the Price/Book (PB) ratio is 3.93.
What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?
The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (DIM.PA) is expected to grow by 19.6% in the next year.